140 related articles for article (PubMed ID: 9274439)
1. The minimal effective exemestane dose for endocrine activity in advanced breast cancer.
Bajetta E; Zilembo N; Noberasco C; Martinetti A; Mariani L; Ferrari L; Buzzoni R; Greco M; Bartoli C; Spagnoli I; Danesini GM; Artale S; Paolini J
Eur J Cancer; 1997 Apr; 33(4):587-91. PubMed ID: 9274439
[TBL] [Abstract][Full Text] [Related]
2. Endocrine and clinical effects of exemestane (PNU 155971), a novel steroidal aromatase inhibitor, in postmenopausal breast cancer patients: a phase I study.
Johannessen DC; Engan T; Di Salle E; Zurlo MG; Paolini J; Ornati G; Piscitelli G; Kvinnsland S; Lonning PE
Clin Cancer Res; 1997 Jul; 3(7):1101-8. PubMed ID: 9815789
[TBL] [Abstract][Full Text] [Related]
3. Twelve-Month Estrogen Levels in Premenopausal Women With Hormone Receptor-Positive Breast Cancer Receiving Adjuvant Triptorelin Plus Exemestane or Tamoxifen in the Suppression of Ovarian Function Trial (SOFT): The SOFT-EST Substudy.
Bellet M; Gray KP; Francis PA; Láng I; Ciruelos E; Lluch A; Climent MA; Catalán G; Avella A; Bohn U; González-Martin A; Ferrer R; Catalán R; Azaro A; Rajasekaran A; Morales J; Vázquez J; Fleming GF; Price KN; Regan MM
J Clin Oncol; 2016 May; 34(14):1584-93. PubMed ID: 26729437
[TBL] [Abstract][Full Text] [Related]
4. Endocrinological and clinical evaluation of exemestane, a new steroidal aromatase inhibitor.
Zilembo N; Noberasco C; Bajetta E; Martinetti A; Mariani L; Orefice S; Buzzoni R; Di Bartolomeo M; Di Leo A; Laffranchi A
Br J Cancer; 1995 Oct; 72(4):1007-12. PubMed ID: 7547212
[TBL] [Abstract][Full Text] [Related]
5. Influence of treatment with the anti-oestrogen 3-hydroxytamoxifen (droloxifene) on plasma sex hormone levels in postmenopausal patients with breast cancer.
Geisler J; Haarstad H; Gundersen S; Raabe N; Kvinnsland S; Lønning PE
J Endocrinol; 1995 Aug; 146(2):359-63. PubMed ID: 7561649
[TBL] [Abstract][Full Text] [Related]
6. Influence of tamoxifen on sex hormones, gonadotrophins and sex hormone binding globulin in postmenopausal breast cancer patients.
Lønning PE; Johannessen DC; Lien EA; Ekse D; Fotsis T; Adlercreutz H
J Steroid Biochem Mol Biol; 1995 May; 52(5):491-6. PubMed ID: 7748814
[TBL] [Abstract][Full Text] [Related]
7. Influence of droloxifene (3-hydroxytamoxifen), 40 mg daily, on plasma gonadotrophins, sex hormone binding globulin and estrogen levels in postmenopausal breast cancer patients.
Geisler J; Ekse D; Hösch S; Lønning PE
J Steroid Biochem Mol Biol; 1995 Nov; 55(2):193-5. PubMed ID: 7495698
[TBL] [Abstract][Full Text] [Related]
8. Effects of exemestane and tamoxifen on hormone levels within the Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial: results of a German substudy.
Hadji P; Kauka A; Bauer T; Tams J; Hasenburg A; Kieback DG
Climacteric; 2012 Oct; 15(5):460-6. PubMed ID: 22321061
[TBL] [Abstract][Full Text] [Related]
9. Safety, activity and estrogen inhibition by exemestane in postmenopausal women with advanced breast cancer: a phase I study.
Paridaens R; Thomas J; Wildiers J; Vermeiren P; Lobelle JP; di Salle E; Ornati G; Zurlo MG; Polli A; Lanzalone S; de Belder K
Anticancer Drugs; 1998 Sep; 9(8):675-83. PubMed ID: 9823425
[TBL] [Abstract][Full Text] [Related]
10. An optimised, highly sensitive radioimmunoassay for the simultaneous measurement of estrone, estradiol and estrone sulfate in the ultra-low range in human plasma samples.
Geisler J; Ekse D; Helle H; Duong NK; Lønning PE
J Steroid Biochem Mol Biol; 2008 Mar; 109(1-2):90-5. PubMed ID: 18242079
[TBL] [Abstract][Full Text] [Related]
11. High activity and tolerability demonstrated for exemestane in postmenopausal women with metastatic breast cancer who had previously failed on tamoxifen treatment.
Kvinnsland S; Anker G; Dirix LY; Bonneterre J; Prove AM; Wilking N; Lobelle JP; Mariani O; di Salle E; Polli A; Massimini G
Eur J Cancer; 2000 May; 36(8):976-82. PubMed ID: 10885600
[TBL] [Abstract][Full Text] [Related]
12. Effects of exemestane and letrozole therapy on plasma concentrations of estrogens in a randomized trial of postmenopausal women with breast cancer.
Robarge JD; Desta Z; Nguyen AT; Li L; Hertz D; Rae JM; Hayes DF; Storniolo AM; Stearns V; Flockhart DA; Skaar TC; Henry NL
Breast Cancer Res Treat; 2017 Feb; 161(3):453-461. PubMed ID: 27943008
[TBL] [Abstract][Full Text] [Related]
13. Endocrine effects of tamoxifen plus exemestane in postmenopausal women with breast cancer.
Love RR; Hutson PR; Havighurst TC; Cleary JF
Clin Cancer Res; 2005 Feb; 11(4):1500-3. PubMed ID: 15746052
[TBL] [Abstract][Full Text] [Related]
14. Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT.
Chia S; Gradishar W; Mauriac L; Bines J; Amant F; Federico M; Fein L; Romieu G; Buzdar A; Robertson JF; Brufsky A; Possinger K; Rennie P; Sapunar F; Lowe E; Piccart M
J Clin Oncol; 2008 Apr; 26(10):1664-70. PubMed ID: 18316794
[TBL] [Abstract][Full Text] [Related]
15. In vivo inhibition of aromatization by exemestane, a novel irreversible aromatase inhibitor, in postmenopausal breast cancer patients.
Geisler J; King N; Anker G; Ornati G; Di Salle E; Lønning PE; Dowsett M
Clin Cancer Res; 1998 Sep; 4(9):2089-93. PubMed ID: 9748124
[TBL] [Abstract][Full Text] [Related]
16. [Late phase II study of exemestane in postmenopausal patients with breast cancer resistant to anti-estrogenic agents].
Watanabe T; Sano M; Toi M; Saeki T; Kanda K; Miura S; Inaji H; Sono H; Saeki H; Nishimura R; Fujita Y
Gan To Kagaku Ryoho; 2002 Jul; 29(7):1211-21. PubMed ID: 12146002
[TBL] [Abstract][Full Text] [Related]
17. Influence of aminoglutethimide on plasma levels of estrone sulphate and dehydroepiandrosterone sulphate in postmenopausal breast cancer patients.
Geisler J; Lien EA; Ekse D; Lønning PE
J Steroid Biochem Mol Biol; 1997; 63(1-3):53-8. PubMed ID: 9449206
[TBL] [Abstract][Full Text] [Related]
18. Influence of dexaminoglutethimide, an optical isomer of aminoglutethimide, on the disposition of estrone sulfate in postmenopausal breast cancer patients.
Geisler J; Lundgren S; Berntsen H; Greaves JL; Lønning PE
J Clin Endocrinol Metab; 1998 Aug; 83(8):2687-93. PubMed ID: 9709932
[TBL] [Abstract][Full Text] [Related]
19. Effect of anastrozole on hormone levels in postmenopausal women with early breast cancer.
Kyvernitakis I; Albert US; Kalder M; Winarno AS; Hars O; Hadji P
Climacteric; 2015 Feb; 18(1):63-8. PubMed ID: 24884402
[TBL] [Abstract][Full Text] [Related]
20. Exemestane (FCE 24304), a new steroidal aromatase inhibitor.
di Salle E; Ornati G; Giudici D; Lassus M; Evans TR; Coombes RC
J Steroid Biochem Mol Biol; 1992 Sep; 43(1-3):137-43. PubMed ID: 1525055
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]